Breast Cancer Test Makers Will Attempt to Sway UK's NICE in Wake of Initial Negative Opinion
February 08, 2012
Breast Cancer Test Makers Will Attempt to Sway UK's NICE in Wake of Initial Negative Opinion
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- In Preliminary Recommendation, UK's NICE Backs Oncotype DX in Subset of Breast Cancer Patients
February 20, 2013 / Pharmacogenomics Reporter - Genomic Health Study Highlights Discrepancy between Oncotype DX and MammaPrint Results
December 19, 2012 / Pharmacogenomics Reporter - Economic Model Finds MammaPrint More Cost-Effective than Oncotype; Highlights Need for Future Studies
May 9, 2012 / Pharmacogenomics Reporter - St. Gallen Experts Recommend Oncotype DX for Chemoprediction; Support Breast Cancer Subtyping
July 27, 2011 / Pharmacogenomics Reporter - After Moving MammaPrint to FFPE Format, Agendia Sees Revenue Boost, Increasing Adoption
April 25, 2012 / Pharmacogenomics Reporter